Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Acura Pharmaceuticals ( (ACUR) ) has shared an update.
On June 3 and June 20, 2025, Acura Pharmaceuticals received loans totaling $200,000 from Abuse Deterrent Pharma, LLC, contributing to a principal balance of $8,194,279 with accrued interest of approximately $721,000. The loans are crucial for maintaining daily operations, but without additional financing by mid-July 2025, Acura may need to scale back operations or consider bankruptcy, potentially resulting in a complete loss of shareholder value.
More about Acura Pharmaceuticals
Acura Pharmaceuticals operates in the pharmaceutical industry, focusing on the development of products utilizing its proprietary LIMITx and Impede technologies. The company is involved in creating abuse-deterrent formulations and has a market focus on addressing opioid abuse.
Average Trading Volume: 6,850
Technical Sentiment Signal: Sell
Current Market Cap: $165K
For detailed information about ACUR stock, go to TipRanks’ Stock Analysis page.